DDD Partners
REGN icon

DDD Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

DDD Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$24.7M Buy
32,587
+284
+0.9% +$215K 1.41% 14
2026
Q2 		$20.1M Buy
32,303
+5,383
+20% +$3.66M 1.26% 29
2026
Q1 		$20.8M Buy
26,920
+2,846
+12% +$2.18M 1.43% 13
2025
Q4 		$18.6M Buy
24,074
+2,713
+13% +$1.84M 1.18% 26
2025
Q3 		$12M Buy
21,361
+865
+4% +$489K 0.76% 39
2025
Q2 		$10.8M Buy
+20,496
New +$11.4M 1.15% 33

Other funds holding REGN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

DDD Partners's REGN Position: Q3 2026 in Review

DDD Partners increased its Regeneron Pharmaceuticals (REGN) stake by 0.88% in Q3 2026, buying an estimated $215K and bringing the position to 32,587 shares worth $24.7M. The position accounts for 1.41% of the portfolio, ranked #14.

DDD Partners first reported a position in REGN in Q2 2025 and has held it in 6 quarters since. 755 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • DDD Partners held 32,587 shares of Regeneron Pharmaceuticals worth $24.7M as of Q3 2026.
  • DDD Partners bought 284 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $215K.
  • Regeneron Pharmaceuticals made up 1.41% of DDD Partners's portfolio in Q3 2026, its #14 holding.
  • DDD Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • 755 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on DDD Partners's 13F filing for Q3 2026, filed 2 Nov 2026.